Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients

Introduction : Significant improvements of leukemia free survival have been obtained over the last 30 years in AML. This progress has resulted from optimization of the same chemotherapy-based "one-size-fits-all" approach. However, even though the majority of patients eligible for intensive chemotherapy achieve complete remission (60% to 80%), the majority still relapse and ultimately die (5-year overall survival being around 20%). Recent genomic...